PEP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PEP is NOT a good buy right now for an impatient buyer. The trend is bullish, but the stock is near resistance with short-term momentum stretched (RSI 70), while insiders and Congress have been net sellers and the next earnings (2026-02-03 pre-market) is a near-term event risk. A better entry would be on a pullback toward the pivot/support area (146.9 / 143.9).
Price/Trend: Pre-market ~148.3 (-0.27%) with the broader market down (S&P -0.42%). Trend structure is bullish with moving averages stacked positively (SMA_5 > SMA_20 > SMA_200), indicating an uptrend across short/medium/long horizons. Momentum: MACD histogram is positive and expanding (0.698), confirming upside momentum. However RSI_6 is ~70.17, which is effectively stretched/near-overbought, suggesting limited immediate upside before consolidation. Levels: Pivot 146.91 is the key line for holding the uptrend. Immediate resistance is R1 149.89 (close overhead) then R2 151.73. Supports are S1 143.93 and S2 142.09. Pattern/forward odds (provided): Similar-pattern study implies a small next-day drift (-0.05%) but positive bias over 1 week (+2.7%) and 1 month (+10.85%).
Intellectia Proprietary Trading Signals
Uptrend remains intact (bullish MA stack + positive MACD), supporting continued medium-term strength.
Defensive/dividend appeal highlighted in news flow; PEP dividend yield ~3.85% cited as attractive vs peers, supporting demand during risk-off markets.
Analyst tone has improved: multiple target raises and notable upgrades (e.g., JPMorgan to Overweight PT $164; BNP Paribas to Outperform PT $179), with upside vs current ~
Potential activist involvement (per BNP) framed as a possible “win-win” setup.
If earnings (2026-02-
confirms organic growth/margin trajectory, it can extend the rally through resistance (~150-152).
Near-term technical stretch: RSI ~70 and price sitting just below key resistance (R1 ~149.
increases pullback/consolidation odds.
Insiders are selling (selling amount up ~364.5% over the last month), a negative signal for near-term conviction.
Congress trading (last 90 days): 12 trades, 0 buys and 12 sells (aggregate $1.7M–$8.0M, median ~$4.9M), indicating influential selling pressure.
Fundamentals recently softened: Q3 2025 net income and EPS down double-digits YoY while gross margin also declined.
Earnings on 2026-02-03 pre-market is a binary catalyst; with IV percentile high, the market is pricing event risk.
Latest reported quarter: 2025/Q3. Revenue rose to $23.94B (+2.65% YoY), showing modest top-line growth. However profitability weakened: net income fell to $2.60B (-11.16% YoY) and EPS declined to 1.90 (-10.80% YoY). Gross margin slipped to 53.91% (-2.93% YoY). Overall: growth is steady but margin/earnings pressure is the key concern going into the next print (QDEC 2025 earnings on 2026-02-03 pre-market; Street EPS est. 2.24).
Recent trend: Net-positive revisions with several price target increases and key upgrades, though not unanimous. Bulls point to improved 2026 outlook, productivity savings, and relative valuation discount (JPMorgan upgrade to Overweight, PT $164; Citi maintains Buy PT $170; Piper maintains Overweight PT up to $172; BNP Paribas upgraded to Outperform PT $179 citing potential activist upside). Bears/neutral view: Barclays stays Equal Weight with a $148 target, characterizing recent strength as “flight to safety” and flagging potential oil/currency headwinds and sector fundamental concerns. Wall Street pros: defensive quality, shareholder return profile, productivity and innovation/marketing plans, potential activist catalyst. Wall Street cons: consumption growth uncertainty, margin pressure, FX/commodity headwinds, and staples valuation/fundamental debate.
